Bufalin is a highly toxic, effective anti-cancer compound, targets Hsp90 cochaperone AHSA1 (Aha1, Activator of HSP90 ATPase Activity 1).
AHSA1-K137 as the specific binding site of Bufalin on AHSA1, mutation of which decreased the interaction of AHSA1 with HSP90A and suppressed the function of AHSA1 on mediating CDK6 and PSMD2.
Bufalin is an anticancer molecular extract from traditional Chinese medicine, exerts significantly experimental anticancer effects in various cancers including MM by inducing cellular apoptotic, autophagic and anti-inflammatory activities.
The potential side effects and toxicities of Bufalin such as hematological, gastrointestinal, mucocutaneous and cardiovascular adverse reactions limit the clinical setting of Bufalin.
